v3.25.3

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 6,150	$ 11,055
Available-for-sale investments	84,052	61,070
Other receivables	1,042	1,736
Prepaid expenses	1,770	8,093
Total current assets	93,014	81,954
Restricted cash	2,712	2,951
Property and equipment, net	4,429	4,850
Operating lease, right-of-use assets	5,603	5,817
Financing lease, right-of-use assets	745	1,192
Other assets	149	66
Total assets	106,652	96,830
Current liabilities:
Accounts payable	4,064	4,323
Accrued expenses	10,185	9,392
Current portion of operating lease liability	799	711
Current portion of financing lease liability	630	541
Total current liabilities	15,678	14,967
Long-term operating lease liability, net of current portion	10,532	11,144
Long-term financing lease liability, net of current portion	398	887
Commitments and contingencies (Note 4)
Stockholders’ equity:
Preferred stock, $0.001 par value per share; 5,000,000 undesignated authorized shares as of September 30, 2025 (unaudited) and December 31, 2024, no shares issued or outstanding as of September 30, 2025 (unaudited) and December 31, 2024
Common stock, $0.001 par value per share; 170,000,000 authorized shares as of September 30, 2025 (unaudited) and December 31, 2024, issued and outstanding shares - 97,986,634 as of September 30, 2025 (unaudited) and 84,038,922 as of December 31, 2024	98	84
Additional paid-in capital	672,339	602,021
Accumulated other comprehensive loss	(1)	(40)
Accumulated deficit	(592,201)	(532,046)
Total aTyr Pharma stockholders’ equity	80,235	70,019
Noncontrolling interest in Pangu BioPharma Limited	(191)	(187)
Total stockholders' equity	80,044	69,832
Total liabilities and stockholders’ equity	$ 106,652	$ 96,830

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

aTYR PHARMA INC 10-Q